PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.26%
Both companies show declining cash positions (-8.26% vs CRVO's -20.77%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-8.26%
Cash + STI yoy ≥ 1.5x CRVO's -4.86%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
≥ 1.5x CRVO's -1.29%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-11.00%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.61%
Higher Long-Term Investments Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.27%
Both CRVO and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
≥ 1.5x CRVO's -1.29%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
18.31%
Less than half of CRVO's -0.81%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.93%
Less than half of CRVO's -53.19%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.43%
Less than half of CRVO's 34.27%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Less than half of CRVO's 17.72%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.76%
Below half CRVO's -8.28%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
≥ 1.5x CRVO's -3.45%. David Dodd sees stronger capital base growth than competitor.
-8.20%
≥ 1.5x CRVO's -1.29%. David Dodd sees faster overall balance sheet growth than competitor.
0.61%
Below half CRVO's 1.89%. Michael Burry suspects major underinvestment or forced divestment.
-9.98%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
8.22%
Less than half of CRVO's 20.77%. David Dodd sees better deleveraging or stronger cash buildup than competitor.